Rep. Alexandria Ocasio-CortezAlexandria Ocasio-CortezTlaib becomes first Muslim woman to preside over House Overnight Energy: Dems press Interior chief to embrace climate action | Lawmakers at odds on how to regulate chemicals in water | Warren releases climate plan for military Overnight Defense: Lawmakers on edge over Iran tensions | Questions rise after State pulls personnel from Iraq | Senators demand briefing | House panel advances 0B Pentagon spending bill | Warren offers plan on climate threats to military MORE (D-N.Y.) confronted a CEO Thursday for pricing a drug designed to reduce the risk of HIV transmission at $8 in Australia but over $1,500 in the U.S.

“You’re the CEO of Gilead. Is it true that Gilead made $3 billion in profits from Truvada in 2018?” Ocasio-Cortez asked Gilead CEO Daniel O’Day.

“$3 billion in revenue,” he clarified.

“The current list price is $2,000 a month in the United States, correct?” she asked, referring to Truvada.

“It’s $1,780 in the United States,” O’Day responded.

“Why is it $8 in Australia?” Ocasio-Cortez countered.

“Truvada still has patent protection in the United States and in the rest of the world it is generic,” O’Day explained, adding, “It will be generically available in the United States as of September 2020.”

“I think it’s important here that we notice that we the public, we the people, developed this drug. We paid for this drug, we lead and developed all the patents to create Prep and then that patent has been privatized despite the fact that the patent is owned by the public, who refused to enforce it,” Ocasio-Cortez said.

“There’s no reason this should be $2,000 a month. People are dying because of it and there’s no enforceable reason for it.”

Truvada is a prophylactic treatment for HIV or AIDs that reduces the risk of infection.

You Might Like
Learn more about RevenueStripe...